Overview

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Status:
Suspended

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating young patients with relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin's lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

MedImmune LLC

Collaborator:

Cambridge Antibody Technology

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoconjugates
Immunoglobulins
Immunotoxins